Key Points
- Biopharma SHAKTI: ₹10,000 crore investment over five years starting FY 2026-27.
- Aims to capture 5% of the global biopharmaceutical market share.
- Includes upgrading NIPERs and developing 1,000 clinical trial sites.
Budget 2026: the Biopharma SHAKTI with an outlay of Rs. 10,000 crores over five years, aimed at strengthening India’s ecosystem for production of biologics and biosimilars. The initiative aligns with the aim of transforming India into a leading global biopharma industry and capturing 5% of the global biopharmaceutical market share.
In the Budget 2026 union government acknowledged the growing burden of non-communicable diseases and the increasing global reliance on biologics and biosimilars, the Budget positions biopharma as a high-value, future-facing segment critical for both public health and economic growth.
Source: PIB
What is the Biopharma SHAKTI Scheme?
In the Union Budget 2026-2027 Finance Minister of India announced the Biopharma SHAKTI initiative to strengthen India’s end-to-end ecosystem for biologics and biosimilars and Make India global Hub of Pharmaceutical. The key features are
-
It is a dedicated national initiative to enhance India’s competitiveness in the global biologics supply chain with an outlay of Rs. 10,000 crores over five years.
-
Designed to support domestic development and manufacturing of high-value biopharmaceutical products and medicines, reduce import dependence.
-
Expansion and strengthening of the Biopharma-focused network through the establishment of three new National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgradation of seven existing NIPERs.
-
Development of 1,000 accredited clinical trial sites across the country to create a large-scale clinical research ecosystem for advanced biologics and biosimilars.
-
Strengthening the Central Drugs Standard Control Organisation( CDSCO) with a dedicated "Scientific Review Cadre" to meet global approval timelines.
Also Read: Budget 2026 Highlights: Summary, Key Points and Download PDF
| Component of Scheme | Detail |
| Budget 2026 Outlay | ₹10,000 Crore |
| Duration | 5 Years (Starting FY 2026-27) |
| Primary Beneficiaries | MSMEs, Biopharma Startups, and Research Institutions |
| Complementary Funding | Linked with the ₹1 Lakh Crore R&D Fund (announced Nov 2025) |
What is Biopharma?
Biopharma, or biopharmaceuticals is a part of the pharmaceutical industry that focuses on developing, extraction of therapies and manufacturing medicines by using biological organisms, such as human cells, fungi, or microbes.
It uses biotechnology-based research methods, these living systems are guided to produce medicines that can prevent, diagnose or treat disease such as biopharmaceuticals including vaccines, antibody treatments, gene therapies, cell implants, modern insulin, and recombinant protein drugs.
-1768807676875.jpg)
Comments
All Comments (0)
Join the conversation